The Cognitive Neuroscience Journal

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - The Cognitive Neuroscience Journal (2023) Volume 6, Issue 5

Translational Neuroscience: Bridging the Gap Between Lab and Clinic

Masahiro Kasai *

Department of Neuroscience, Kobe University Graduate School of Medicine, Kobe, Japan

*Corresponding Author:
Masahiro Kasai
Department of Neuroscience
Kobe University Graduate School of Medicine
Kobe, Japan
E-mail: Kasai@ac.jp

Received:30-Sept-2023, Manuscript No. AACNJ-23-115914; Editor assigned:03-Oct-2023, PreQC No. AACNJ-23-115914 (PQ); Reviewed:18-Oct-2023, QC No. AACNJ-23-115914; Revised:24-Oct-2023, Manuscript No. AACNJ-23-115914 (R); Published:31-Oct-2023, DOI:10.35841/ aacnj-6.5.174

Citation: Kasai M. Translational neuroscience: Bridging the gap between lab and clinic. J Cogn Neurosci. 2023;6(5):174

Visit for more related articles at The Cognitive Neuroscience Journal

Introduction

Neuroscience, the study of the brain and nervous system, has made tremendous strides in understanding the complexities of the human mind. However, translating this knowledge into real-world treatments and therapies is a challenge that requires a bridge between the laboratory and the clinic. This bridge is known as translational neuroscience, a field dedicated to translating scientific discoveries into tangible benefits for individuals with neurological disorders and mental health conditions. In this article, we explore the significance of translational neuroscience and how it is shaping the future of brain-related healthcare. Translational neuroscience can be thought of as a two-way street. On one side, it involves taking insights and discoveries from basic neuroscience research, often conducted in laboratories, and translating them into practical applications for clinical practice. On the other side, it involves identifying clinical challenges and questions that need answers and then conducting research to find solutions, ultimately bringing these findings back to the clinic [1].

Basic Science to Clinical Application (T1) in the first phase, researchers in basic science laboratories explore fundamental questions about the brain and nervous system. This research can include studies on the molecular and cellular level, as well as animal models. The goal is to identify potential targets for treatment. Clinical Application to Patients (T2) once potential treatments or interventions are identified in the laboratory, they move into the second phase, which involves testing in clinical trials with human participants. This phase assesses the safety and efficacy of these interventions. Translation into Practice (T3) the third phase focuses on implementing evidence-based practices and treatments in the real-world clinical setting. This involves disseminating knowledge to healthcare providers, developing clinical guidelines, and ensuring that treatments proven effective in trials are accessible to patients [2].

The importance of translational neuroscience

 

Translational neuroscience plays a pivotal role in addressing the significant burden of neurological and mental health disorders. Here's why it is essential: Bringing Hope to Patients: For individuals living with conditions like Alzheimer's disease, Parkinson's disease, schizophrenia, and depression, translational neuroscience offers hope for improved treatments and better quality of life [3].

 

Accelerating Discovery by streamlining the process of moving from basic research to clinical practice, translational neuroscience accelerates the discovery and development of new therapies. Precision Medicine It allows for a more personalized approach to treatment, tailoring interventions to the unique needs of each patient based on their genetic, molecular, and clinical profiles. Addressing Unmet Needs Translational neuroscience is particularly crucial for conditions with limited treatment options or where existing treatments have significant limitations. Several notable successes in translational neuroscience highlight its potential Deep Brain Stimulation (DBS) originally developed for movement disorders like Parkinson's disease, DBS is now being explored as a treatment for depression, obsessive-compulsive disorder, and other psychiatric conditions. Monoclonal Antibodies Advances in antibody-based therapies have opened new possibilities for treating neurodegenerative diseases like Alzheimer's and multiple sclerosis. Pharmacogenomics tailoring medication choices based on an individual's genetic makeup is becoming increasingly important in psychiatry, helping to improve the effectiveness of treatments for conditions like depression and schizophrenia [4].

 

Challenges and future directions

 

Translational neuroscience faces challenges such as funding limitations, the need for multidisciplinary collaboration, and the complexity of neurological disorders. However, as technology advances and our understanding of the brain deepens, the potential for breakthroughs in this field is vast. In the coming years, we can expect to see more personalized and effective treatments for neurological and mental health conditions as translational neuroscience continues to bridge the gap between the laboratory and the clinic. As researchers and healthcare professionals work hand in hand, the future holds promise for better outcomes and improved quality of life for individuals facing brain-related challenges [5].

References

  1. Treadway MT, Zald DH. Reconsidering anhedonia in depression: Lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537-55.

    2. Indexed at, Google Scholar, Cross Ref

  2. de Vico Fallani F, Richiardi J, Chavez M, et al. Graph analysis of functional brain networks: practical issues in translational neuroscience. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 2014;369(1653):20130521.

    3. Indexed at, Google Scholar, Cross Ref

  3. Brayne C, Barker RA, Harold D, et al. From molecule to clinic and community for neurodegeneration: research to bridge translational gaps. J. Alzheimer's Dis. 2013 Jan 1;33(s1):S385-96.

    4. Indexed at, Google Scholar, Cross Ref

  4. Pober JS, Neuhauser CS, Pober JM. Obstacles facing translational research in academic medical centers. The FASEB J. 2001;15(13):2303-13.

    5. Indexed at, Google Scholar

  5. Gevaert T, Vriens J, Segal A, et al. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest. 2007;117(11):3453-62.

    6. Indexed at, Google Scholar, Cross Ref

Get the App